Dixon-Based Water T1 Mapping for Fat-Corrected Assessment of Hepatic Fibrosis in Chronic Liver Disease
- PMID: 40476782
- DOI: 10.1097/RLI.0000000000001212
Dixon-Based Water T1 Mapping for Fat-Corrected Assessment of Hepatic Fibrosis in Chronic Liver Disease
Abstract
Objectives: The diagnostic value of conventional T1 mapping for noninvasive assessment of liver fibrosis is limited in the presence of hepatic steatosis. To evaluate the diagnostic value of water T1 (wT1) with continuous inversion-recovery Look-Locker (CIR-LL) method, integrating spiral readout, Dixon, and dictionary-based processing, for the fat-corrected assessment of hepatic fibrosis in patients with chronic liver disease (CLD).
Materials and methods: In this prospective study, consecutive participants with CLD underwent liver magnetic resonance imaging (MRI), which included assessment of MR-elastography (MRE)-derived liver stiffness, proton density fat fraction (PDFF), T1 relaxation times using modified Look-Locker inversion recovery (T1-MOLLI) and extracellular volume fraction (ECV), and wT1 relaxation times. MRE served as the reference standard to evaluate the diagnostic performance of MRI-based mapping parameters. Significant fibrosis (≥F2) was defined as MRE-derived liver stiffness >3.66 kPa in patients with PDFF≤5%, or >3.14 kPa in patients with PDFF>5%. Statistical analysis included Student t test, receiver operating characteristic (ROC) analysis, and Spearman correlation coefficient.
Results: A total of 81 CLD patients (mean age, 50±14 y; 32 female; 40 patients with PDFF>5%) were included. All measured mapping values were significantly higher in patients with significant fibrosis compared with those without (eg, wT1: 628±82 vs. 546±41 ms, P<0.001). wT1 showed a strong correlation with MRE-derived liver stiffness, outperforming T1-MOLLI and ECV mapping [whole cohort: r=0.67 (wT1) vs. 0.53 (T1-MOLLI) vs. 0.48 (ECV); cohort with PDFF>5%: r=0.69 (wT1) vs. 0.44 (T1) vs. 0.49 (ECV); P<0.05 in each case, respectively]. wT1 had a superior diagnostic performance for the detection of significant fibrosis [whole cohort, area under the curve (AUC): 0.82 (wT1); 0.77 (T1-MOLLI); 0.73 (ECV), P<0.001 in each case; cohort with PDFF>5%, AUC: 0.84, P=0.002 (wT1), 0.70, P=0.04 (T1-MOLLI), 0.70, P=0.04 (ECV)].
Conclusion: Compared with T1-MOLLI and ECV mapping, the proposed fat-corrected CIR-LL wT1 method proved to be a more robust marker of hepatic fibrosis in CLD, also in the presence of hepatic steatosis.
Keywords: chronic liver disease; fibrosis; liver magnetic resonance imaging; quantitative multiparametric mapping.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest and sources of funding: none declared.
Similar articles
-
Native and Gd-EOB-DTPA-Enhanced T1 mapping for Assessment of Liver Fibrosis in NAFLD: Comparative Analysis of Modified Look-Locker Inversion Recovery and Water-specific T1 mapping.Acad Radiol. 2025 Jan;32(1):170-179. doi: 10.1016/j.acra.2024.07.009. Epub 2024 Jul 23. Acad Radiol. 2025. PMID: 39043516
-
MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction.Diagn Interv Radiol. 2021 Jan;27(1):7-14. doi: 10.5152/dir.2020.19654. Diagn Interv Radiol. 2021. PMID: 33290237 Free PMC article.
-
MRI Dixon Fat-Corrected Look-Locker T1 Mapping for Quantification of Liver Fibrosis and Inflammation-A Comparison With the Non-Fat-Corrected Shortened Modified Look-Locker Inversion Recovery Technique.Invest Radiol. 2024 Nov 1;59(11):754-760. doi: 10.1097/RLI.0000000000001084. Invest Radiol. 2024. PMID: 39514773 Free PMC article.
-
Non-invasive assessment of liver fibrosis in autoimmune hepatitis: Diagnostic value of liver magnetic resonance parametric mapping including extracellular volume fraction.Abdom Radiol (NY). 2021 Jun;46(6):2458-2466. doi: 10.1007/s00261-020-02822-x. Epub 2020 Oct 19. Abdom Radiol (NY). 2021. PMID: 33078245 Free PMC article.
-
Diagnostic value of magnetic resonance parametric mapping for non-invasive assessment of liver fibrosis in patients with primary sclerosing cholangitis.BMC Med Imaging. 2021 Apr 7;21(1):65. doi: 10.1186/s12880-021-00598-0. BMC Med Imaging. 2021. PMID: 33827475 Free PMC article.
References
-
- Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516–537.
-
- Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology (Baltimore, Md). 2024;79:666–673.
-
- Mesropyan N, Kupczyk P, Dold L, et al. Non-invasive assessment of liver fibrosis in autoimmune hepatitis: diagnostic value of liver magnetic resonance parametric mapping including extracellular volume fraction. Abdom Radiol (NY). 2021;46:2458–2466.
-
- Mesropyan N, Kupczyk P, Kukuk GM, et al. Diagnostic value of magnetic resonance parametric mapping for non-invasive assessment of liver fibrosis in patients with primary sclerosing cholangitis. BMC Med Imaging. 2021;21:65.
-
- Mesropyan N, Kupczyk PA, Dold L, et al. Assessment of liver cirrhosis severity with extracellular volume fraction MRI. Sci Rep. 2022;12:9422.
LinkOut - more resources
Full Text Sources
Miscellaneous